Agalsidase Alfa: A Review of its Use in the Management of Fabry Disease

ISSN： 1173-8804

Source： BioDrugs, Vol.26, Iss.5, 2012-10, pp. : 335-354

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Spotlight on Agalsidase Beta in Fabry Disease

By Keating Gillian M. Simpson Dene

BioDrugs, Vol. 21, Iss. 4, 2007-01 ,pp. : 269-271

Adis International

Access to resources Recommend Favorite

Darbepoetin Alfa: Its Use in Anemia Associated with Chronic Kidney Disease

By Robinson Dean M. Easthope Stephanie E.

BioDrugs, Vol. 19, Iss. 5, 2005-01 ,pp. : 327-343

Adis International

Access to resources Recommend Favorite

Corifollitropin Alfa: A Review of its Use in Controlled Ovarian Stimulation for Assisted Reproduction

By Croxtall Jamie D. McKeage Kate

BioDrugs, Vol. 25, Iss. 4, 2011-08 ,pp. : 243-254

Adis International

Access to resources Recommend Favorite

Octocog Alfa (Advate®): A Guide to Its Use in Hemophilia A

By Keating Gillian M. Dhillon Sohita

BioDrugs, Vol. 26, Iss. 4, 2012-08 ,pp. : 269-273

Adis International

Access to resources Recommend Favorite

Fabry Disease: Recognition and Management of Cutaneous Manifestations

By Möhrenschlager M. Braun-Falco M. Ring J. Abeck D.

American Journal of Clinical Dermatology, Vol. 4, Iss. 3, 2003-01 ,pp. : 189-196

Adis International

Access to resources Recommend Favorite